Rituxan Sales Data
| Rank 12 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Rituxan U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 12 ( 1) |
$798,989 | 1.25% | 545 | 1.30% |
| Q3 2013 | 11 | $789,123 | -4.46% | 538 | -5.78% |
| Q2 2013 | 11 | $825,949 | 3.96% | 571 | 1.96% |
| Q1 2013 | 11 | $794,464 | 1.98% | 560 | 1.82% |
| Q4 2012 | 11 | $779,026 | 0.72% | 550 | -1.26% |
| Q3 2012 | 11 ( 1) |
$773,460 | -5.61% | 557 | -3.30% |
| Q2 2012 | 12 (3) |
$819,418 | 8.26% | 576 | 5.30% |
| Q1 2012 | 15 (1) |
$756,875 | -1.91% | 547 | -0.91% |
| Q4 2011 | 14 (2) |
$771,622 | 6.96% | 552 | 4.74% |
| Q3 2011 | 16 | $721,408 | -1.77% | 527 | -1.86% |
| Q2 2011 | 16 (4) |
$734,378 | 7.26% | 537 | 5.09% |
| Q1 2011 | 20 | $684,666 | n/a | 511 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
